Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2023-04-21 Interim / Quarterly Rep…
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Q1 statement / Q1 financial report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report as at 31.03.2023' and contains comprehensive financial data, including consolidated interim financial statements, performance comparisons, and a shareholder letter detailing the company's activities for the first quarter. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-04-21 English
Shareholders at BB Biotech AGs AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
Notice of Dividend Amount Classification · 99% confidence The document explicitly mentions 'BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share' and uses the keyword 'AGM/EGM'. This indicates the content relates directly to the proceedings and outcomes of the Annual General Meeting. Since it reports the results of shareholder votes on proposals (including the dividend approval and board re-elections), the most specific category is AGM Information (AGM-R). Although it mentions dividend approval, the primary context is the meeting itself, not just a standalone dividend notice (DIV). It is not a full 10-K, an earnings release, or a proxy statement, but a summary of the AGM results.
2023-03-23 English
EQS-News: In occasione dell’Assemblea generale annuale di BB Biotech AG gli azionisti hanno votato a favore di tutte le proposte presentate e approvato il dividendo di CHF 2.85 per azione
Notice of Dividend Amount Classification · 99% confidence The document text explicitly mentions 'Assemblea generale annuale' (Annual General Meeting) and details the outcomes, including shareholder votes on all proposals and the approval of a specific dividend amount (CHF 2.85 per share). The title also contains 'Assemblea generale/Dividendi'. This strongly indicates that the content relates to the proceedings and results of the AGM. While dividends are mentioned (DIV) and board members were reconfirmed (MANG), the primary context is the meeting itself. The most specific category for materials related to the AGM is 'AGM-R' (AGM Information). Since this is a summary of the results, it fits the AGM-R definition better than a general Regulatory Filing (RNS) or a specific Dividend Notice (DIV). The document length is relatively short, but it summarizes the meeting's outcome rather than just announcing that a report is available.
2023-03-23 Italian
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
Notice of Dividend Amount Classification · 99% confidence The document explicitly mentions 'BB BIOTECH AG / Key word(s): AGM/EGM/Dividend' and the headline states, 'Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share'. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM), including shareholder votes and dividend approval. This aligns perfectly with the definition for AGM Information (AGM-R). Although dividend information is present, the primary context is the AGM outcome.
2023-03-23 English
EQS-News: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 2.85 pro Aktie
AGM Information Classification · 99% confidence The document text explicitly mentions 'Generalversammlung' (General Meeting) multiple times, states that shareholders approved all proposals, and specifically details the approval of a dividend ('genehmigt die Dividende von CHF 2.85 pro Aktie'). It also mentions the re-election of Board members. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). Although dividend information (DIV) and board changes (MANG) are mentioned, the overarching context is the AGM resolution itself.
2023-03-23 German
Edison issues review on BB Biotech (BION)
Report Publication Announcement Classification · 99% confidence The document is an announcement disseminated via RNS (RNS Number: 1401S) and explicitly states it is provided by 'Reach, the non-regulatory press release distribution service of RNS'. The content is an 'Edison issues review on BB Biotech (BION)' and includes links to view the full report published by Edison. Since the document itself is a short announcement (4967 characters) whose primary function is to notify the market that a research report has been published, it fits the definition of a Report Publication Announcement (RPA). It is not the full report (like 10-K or IR), nor is it a standard regulatory filing, but rather an announcement about external research publication.
2023-03-07 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.